CRSP's Quality Score rose 2 points on Mon, Nov 2, to -8.
Follow CRSP's trial news. Pro members can get an alert when CRISPR Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 46% over five years while the S&P 500 rose 76%.
−3Insider trades
| Holding it back | Sales down 65% on the year |
| Latest filing | 8-K, Nov 2 |
ReportToday after the close: sales of $12.7M; a loss of $1.15 a share. Past reports ›
CRISPR Therapeutics AG filed an 8-K reporting a change of CFO
CRSP closed −0.3% the next session (Oct 20).
Fri Nov 6: American Heart Association (AHA)…Industry event · date confirmed.
1 more date ahead: the conference, for Pro members.
After its last 3 reports it closed +4.4% on average, higher 2 of 3 times.
Over 5 years
No shelf registration or at-the-market program on file in the last three years.
CEO Samarth Kulkarni sold 47,837 shares on Oct 19. 21 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
CRSP is #271 of 291 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 271 |
Net income over four quarters: CRSP -$451M, TARS -$46.5M, BEAM -$85.4M, KOD -$242M.
Expected to report Mon Nov 9, after the close (in 7 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
Sales of $12.7M; a loss of $1.15 a share, from $1.17.
“The increase in cash was primarily driven by net proceeds of $585.4 million from the issuance of convertible senior notes in March 2026, offset by operating expenses.”
CRSP's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The increase in R&D expense was primarily attributable to an increase in external research and development expenses and sublicense fees, offset by a decrease in employee-related costs.”
From its results filing (SEC filing · Nov 2)
Its share count grew 6.4% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Aug 3, 2026 | +2.0% | +7.1% | +8.0% |
| May 4, 2026 | -1.8% | -2.2% | +0.8% |
| Feb 12, 2026 | +1.7% | +8.5% | +9.3% |
Sales grew in three of the last seven years, to $3.5M in 2025. It made a profit in two of the eight years.
4 insiders sold $3.6M across 5 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
“The biotechnology and pharmaceutical industries, including in the gene editing, gene therapy, nucleic acids therapies, and cell therapy fields, are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products.”
CRSP scores -8 today, which Breakaway calls Poor. It is #271 of 291 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 46% over five years while the S&P 500 rose 76%. Cash lasts over 5 years at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
CRSP scores -8 today, which Breakaway calls Poor (below zero). That is #271 of 291 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CRSP's -8.
4 insiders sold $3.6M across 5 filings in the last 6 months. No open-market buys on record. The newest is Samarth Kulkarni, Chief Executive Officer, who sold $2.4M on Oct 19. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.